MEAL: Metabolomics Characterization of Biomarkers of ASCVD and Prediction Model

Sponsor
Shanghai 10th People's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05148182
Collaborator
(none)
1,869
2
36
934.5
26

Study Details

Study Description

Brief Summary

  1. Describe the risk factors and metabonomics characteristics of atherosclerotic cardiovascular disease in Chinese patients.

  2. Establish accurate prediction model of atherosclerotic heart disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    According to the Chinese cardiovascular disease report released in 2017, cardiovascular disease death is the leading cause of death of urban and rural residents, so cardiovascular disease risk assessment is particularly important. The development of cardiovascular risk assessment model was dated from Framingham Heart Study which first proposed the concept of risk factors, and then adjusted the model several times. In 2016, the China-PAR evaluated the cardiovascular disease risk of Chinese population. However, the application of metabolomics in coronary heart disease is a rapidly developing field and also a new field .

    Therefore, the aim of this study was to

    1.Describe the risk factors of atherosclerotic cardiovascular disease and the characteristics of metabolomics in Chinese population.

    1. Establish an accurate prediction model of atherosclerotic heart disease. Research plan:

    2. 1869 risk-stratified people were recruited.

    3. Plasma samples were collected incluing disease status and other potential influencing factors.

    4. Through the high-throughput detection of body metabolites, combined with multivariate statistical analysis, the metabolic markers with significant difference in different risk levels were screened for risk prediction.

    5. All recruited people underwent coronary angiography.

    6. The distribution of age and gender in each group should be matched and balanced as far as possible.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1869 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Metabolomics Characterization of Biomarkers of ASCVD and Prediction Model
    Anticipated Study Start Date :
    Dec 15, 2021
    Anticipated Primary Completion Date :
    Dec 15, 2024
    Anticipated Study Completion Date :
    Dec 15, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    low risk

    According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.

    medium risk

    According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.

    high risk

    According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.

    Outcome Measures

    Primary Outcome Measures

    1. Metabolomics Characterization of Biomarkers [3 years]

      Metabonomics analysis uses a non targeted detection method to detect polar compounds and lipid compounds in blood. The characteristic peaks of substances that can be detected are detected by chromatography Series platform, and then these characteristic peaks are compared with the standard library containing more than 8000 metabolites to annotate the compounds and screen out the differential metabolites between groups.

    2. Coronary vascularization. [3 years]

      Coronary vascularization includes percutaneous coronary intervention, or/and percutaneous coronary artery dilatation, or/and percutaneous coronary artery bypass grafting.

    3. All cause mortality [3 years]

      which refers to the total death caused by various causes in a certain period.

    4. Cardiac mortality [3 years]

      Cardiac death refers to the death caused by serious cardiac dysfunction or failure which caused by heart disease or injury in a certain period.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. The age of the population is 18 or more than 18 years old.

    2. According to China PAR equations, Chinese guidelines and consensus on cardiovascular risk assessment and management,it is considered as healthy, low, medium, high and extremely high risk group.

    3. The subjects read and fully understood the patient's instructions and signed the informed consent

    Exclusion Criteria:
    1. Refused to sign informed consent.

    2. ACS is caused by surgery, trauma, or other diseases.

    3. Age less than 18 years old.

    4. Pregnant women.

    5. In the past 3 months, the patients were treated with trauma surgery.

    6. There are aortic dissection, pulmonary embolism, pneumonia, pericarditis, myocarditis, stress cardiomyopathy.

    7. Severe heart failure.

    8. Liver and kidney failure.

    9. Blood borne infectious diseases: including HIV / AIDS, hepatitis B, hepatitis C, etc.

    10. Patients with a history of malignancies, autoimmune diseases, severe infectious diseases and trauma.

    11. Any condition (such as travel, speech disorder, mental disorder) that the researcher believes can significantly limit the completion of the patient's follow-up.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Cardiology,Shanghai Tenth People's Hospital Shanghai China 200072
    2 Shanghai Tenth People's Hospital Shanghai China 200072

    Sponsors and Collaborators

    • Shanghai 10th People's Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ya-Wei Xu, Chief Physician, Shanghai 10th People's Hospital
    ClinicalTrials.gov Identifier:
    NCT05148182
    Other Study ID Numbers:
    • MEAL
    First Posted:
    Dec 8, 2021
    Last Update Posted:
    Dec 8, 2021
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ya-Wei Xu, Chief Physician, Shanghai 10th People's Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 8, 2021